Iulia Slovenski

Mrs. Iulia Slovenski

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMarcela Fogaça Vieira
Marcela Fogaça Vieira
ISIulia Slovenski
Iulia Slovenski
KLKaitlin Large
Kaitlin Large
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
SMSuerie Moon
Suerie Moon
Alternative innovation models have emerged to address failures of the traditional pharmaceutical system, particularly for diseases where market incentives do not attract sufficient research and development efforts. However, the feasibility of such models for diseases with significant markets is not well-established. This article analyses the development of a novel drug (ravidasvir) for the treatment of hepatitis C, a highly profitable market. Data from qualitative research methods, including literature reviews and semi-structured interviews, was analyzed using a novel conceptual framework focusing on actors, resources, organizational practices, and outcomes. Dissimilar to other projects, ravidasvir did not involve any major pharmaceutical companies. Rather, it leveraged the capacities of actors less traditionally involved in the development of novel medicines by constructing a collaborative network of private and public partners from low- and middle-income countries with a shared goal. The collaboration was successful in developing a highly effective, easy-to-use, and affordable medicine and contributed significantly to capacity-strengthening. However, the case also highlighted that strategic behavior by competing for-profit firms could pose significant challenges and that changing external conditions reduced the potential public health impact of the drug. Lessons from ravidasvir can inform future efforts to develop alternative innovation models for therapeutic areas with significant commercial interest.

16 January 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
SMSuerie Moon
Suerie Moon
ARAdrian Alonso Ruiz
Adrian Alonso Ruiz
MVMarcela Fogaça Vieira
Marcela Fogaça Vieira
KLKaitlin Large
Kaitlin Large
ISIulia Slovenski
Iulia Slovenski
The current mainstream pharmaceutical innovation system (PIS) is driven by the market-based logic of charging the highest prices societies will bear. Outcomes include unaffordable medicines, restricted access and pressure on health budgets. How can the innovation system change to deliver fairly-priced medicines? We inductively developed a novel conceptual framework of the PIS as a complex adaptive system (CAS) analogous to a forest. We constructed a database of 140 pharmaceutical innovation initiatives that sought to address global public interest objectives such as fair pricing or missing innovation. We found a critical mass of initiatives clustered around four areas: pandemic preparedness, neglected diseases, rare diseases and antibiotics, which we conceptualised as niches within the ecosystem. We reviewed the literature on how each niche had emerged and evolved, conducted interviews, and organised workshops with experts on each niche. Finally, we identified from the literature an initial list of ‘levers’ of change in the PIS, supplemented them with additional levers found in each niche, then compared across niches. We found that actors created niches in the broader system by purposefully problematising an issue, then pulling on one or more of three levers: mobilising new resources, changing the roles of or creating new actors, and/or changing societal norms or legal rules. A wide range of actors – including governments, funders, R&D practitioners, or civil society groups – could pull these levers, and the order in which they were pulled was not fixed, consistent with a CAS. Parts of the vast pharmaceutical innovation system have changed to deliver more affordable medicines by design. Such change has occurred largely within specialised niches, responding to evolving societal norms about the purpose of pharmaceutical innovation. Actors can achieve larger-scale change by further expanding and/or solidifying these niches through changes to resources, actor roles, norms and rules.

20 December 2024 in Discover Public Health
Verified
Journal Article
Open access
PDF file
ISIulia Slovenski
Iulia Slovenski
NWNadya Wells
Nadya Wells
DEDavid Evans
David Evans
Caesarean sections (CSs) are essential surgical procedures that can save lives during childbirth, but can also pose health risks for mothers and infants. H

27 November 2025 in Humanities and Social Sciences Communications
Verified
Journal Article
Open access
PDF file
ISIulia Slovenski
Iulia Slovenski
ARAdrián Alonso Ruiz
Adrián Alonso Ruiz
MVMarcela Vieira
Marcela Vieira
KLKaitlin Elizabeth Large
Kaitlin Elizabeth Large
ASAdam Strobeyko
Adam Strobeyko
SMSuerie Moon
Suerie Moon
Accelerating the development, equitable access to, and stewardship of new antibiotics is critical to protect public health and address antimicrobial resistance (AMR). To understand and assess how the current antibiotics innovation sub-system – or ‘niche’ – addresses this task, we reviewed the literature, compiled and analyzed a database of 211 antibiotic developers, and conducted 10 stakeholder interviews. We found that the mainstream market-driven innovation model is still adopted by a substantial minority of antibiotic developers, but the majority of developers adopt one of two alternative models: The Publicly-Supported Private Initiative (PSPI) model is the most common, and is characterized by public and/or philanthropic financial and other support to small and medium enterprises. This model secures essential resources for R&D, but the current focus on innovation fails to ensure access and stewardship on a national or global scale. The Collaborative Network (CN) alternative innovation model includes a wider range of actors sharing resources and collaborating towards achieving innovation, access and stewardship goals. It consists of public and private actors supported by philanthropic and/or not-for-profit organizations such as Wellcome, CARB-X, or GARDP. We conclude that this model represents the most promising development to ensure innovation with access and stewardship. However, the model is relatively recent and must still demonstrate its capacity to deliver these outcomes. The rules and norms that govern the antibiotic niche are evolving, and policy decisions such as the adoption of pull incentives may profoundly influence which models may succeed in the future. Decision-makers should construct rules and incentives that create conducive conditions for models that jointly deliver innovation, access and stewardship of antibiotics, to help them improve, survive, and thrive.

26 June 2026 in BMJ Innovations
Verified
Journal Article
Open access
SMSuerie Moon
Suerie Moon
ISIulia Slovenski
Iulia Slovenski
ARAdrián Alonso Ruiz
Adrián Alonso Ruiz
MVMarcela Vieira
Marcela Vieira
KLKaitlin Elizabeth Large
Kaitlin Elizabeth Large
Introduction: Discontent with the mainstream commercial pharmaceutical innovation system’s shortcomings (eg, missing innovation, high prices, limited availability) has catalysed experimentation with alternative innovation models (AIMs). However, the study of AIMs is conceptually and empirically fragmented, with open questions regarding definitions, therapeutic focus, functioning, achievements and comparison with the mainstream. Methods: We defined AIMs as having a public interest mission and differing from the mainstream model, for instance, in organisational form, financing, priority setting, role in research and development phases, knowledge management, and regulatory, manufacturing or pricing strategy. We constructed a database of 138 initiatives, conducted interviews with 47 and carried out case studies of three. We iteratively developed novel conceptual frameworks at the system, model and initiative levels and used framework analysis to analyse the data. Results: We found ample evidence that AIMs can develop new medicines addressing unmet health needs. AIMs cluster in four ‘niches’ in the innovation system: pandemic preparedness, neglected tropical diseases, rare diseases and antibiotics. AIM initiatives have in common a public interest mission but vary widely in their organisational form and strategies. Nevertheless, we discerned three archetypal AIMs: national government driven, socially redirected private sector and collaborative network, each able to deliver innovation but with different strengths and weaknesses for meeting the public interest. Conclusions: AIMs have demonstrated their feasibility, advantages and potential to challenge the mainstream model but remain small scale and relatively fragile. Institutionalising them requires stable expanded public and philanthropic financing; enhanced sharing of scientific, regulatory and manufacturing knowledge; and legal and policy changes that secure the resources they need to deliver.